Gujarat Kidney IPO Opens: Price, GMP & Subscription Details

Gujarat Kidney IPO: ₹251 Crore Issue Opens with Strong Retail Demand; Know All Details, Financials, and Latest GMP

The Indian healthcare sector continues to witness significant activity on Dalal Street as the Initial Public Offering (IPO) of Gujarat Kidney and Super Speciality Limited opened for subscription today, December 22, 2025. This ₹251 crore public issue, which will remain open until December 24, has already begun to see robust interest, particularly fro>m individual retail investors looking to capitalize on the growing regional healthcare market.

Day 1 Subscription Status: Retail Investors Lead the Charge

As of the afternoon of the first day, the IPO is receiving an enthusiastic response. According to exchange data (NSE/BSE), by 2:54 PM, the issue was subscribed approximately 0.94 times overall. However, the standout performer is the Retail Individual Investors (RII) category, which has already been oversubscribed 3.83 times.

The Non-Institutional Investors (NII) portion also showed healthy momentum, being subscribed 1.23 times. While the Qualified Institutional Buyers (QIB) segment often sees activity pick up on the final day, the early numbers suggest a high level of confidence among smaller investors in the company’s regional growth story.

Key IPO Details: Price Band, Lots, and Dates

For those looking to participate, here are the essential numbers for the Gujarat Kidney IPO:

• Issue Size: ₹250.80 Crore (Entirely a Fresh Issue of 2.20 crore shares).

• Price Band: ₹108 to ₹114 per equity share.

• Lot Size: Minimum of 128 shares.

• Minimum Investment: ₹14,592 (at the upper price band).

• Subscription Dates: December 22 – December 24, 2025.

• Basis of Allotment: Expected on December 26, 2025.

• Listing Date: Tentatively scheduled for December 30, 2025, on both BSE and NSE.

Because this is a 100% fresh issue, the company will receive all the proceeds to fund its expansion plans, with no existing promoters or investors selling their stake (Zero Offer for Sale).

Strategic Use of Funds: Aggressive Expansion in Gujarat

Gujarat Kidney and Super Speciality Limited operates a network of 7 multi-specialty hospitals and 4 pharmacies across central Gujarat (including Vadodara, Godhra, Bharuch, Borsad, and Anand). The company’s growth strategy focuses on a “roll-up” model—acquiring existing hospitals to scale faster than building from scratch.

The IPO proceeds are earmarked for several high-impact projects:

1. Parekh Hospital Acquisition: Approximately ₹77 crore will be used to acquire Parekhs Hospital in Ahmedabad, marking a major entry into the state’s largest city.

2. New Facility in Vadodara: ₹30.1 crore is allocated for a new hospital project (specifically a Women’s Hospital) in Vadodara.

3. Technological Upgrades: ₹6.8 crore will be spent on advanced robotic medical equipment to enhance surgical precision.

4. Subsidiary Stake: ₹10.78 crore to increase the company’s stake in Harmony Medicare (Bharuch).

5. Debt Repayment: A small portion of ₹1.2 crore will go toward clearing secured borrowings.

Financial Health: High Growth, Sharp Margins

The company has reported a staggering jump in its financial performance leading up to the IPO.

• Revenue: Scaled from ₹4.77 crore in FY24 to ₹40.24 crore in FY25, a growth of over 600%.

• Profit After Tax (PAT): Increased from ₹1.71 crore to ₹9.50 crore in the same period.

• Profitability: The company maintains a healthy EBITDA margin of approximately 41% and a Return on Equity (ROE) of 36.6%.

While these numbers are impressive, some analysts note that the sharp increase comes from a low base and reflects the recent integration of acquired facilities. The sustainability of these margins will be a key factor for long-term investors.

Grey Market Premium (GMP) and Market Sentiment

In the unlisted market, the Grey Market Premium (GMP) for Gujarat Kidney IPO is currently hovering around ₹3 to ₹7, indicating a premium of roughly 3% to 6% over the upper price band.

While the GMP has fluctuated slightly since earlier in the week, the overall sentiment remains positive, especially given the “Zero OFS” structure which aligns management interests with new shareholders.

Expert View: Opportunities vs. Risks

Market analysts have offered a mixed but cautious outlook. On one hand, the company’s focus on Renal Sciences (Kidney Care) and Urology provides a “sticky” patient base with high repeat visits for dialysis. Its asset-light model and regional dominance in central Gujarat are seen as strong competitive advantages.

On the other hand, some experts, including those from Swastika Investmart, have pointed out that the IPO is aggressively valued at a P/E multiple of approximately 61x, which is higher than established peers like Yatharth Hospital or KMC Speciality. Investors are advised to consider the execution risk associated with such rapid inorganic expansion.

Bottom Line: The Gujarat Kidney IPO is an opportunity for those looking to invest in a fast-growing, regional healthcare player. While the retail excitement is high, investors should weigh the high valuations against the company’s strong recent profitability and clear expansion roadmap.